Skip to main content

Table 2 Clinical response to pyrotinib in NSCLC patients with HER2 mutation

From: Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial

Variable  
Best response, n (%)  
Partial response 15 (19.2)
Stable disease 43 (55.1)
Progressive disease 20 (25.6)
Objective response rate, % (95% CI) 19.2 (11.2–30.0)
Disease control rate, % (95% CI) 74.4 (63.2–83.6)
Duration of response, median (95% CI) 9.9 (6.2–13.6)
Progression-free survival  
Events, n (%) 50 (64.1)
Median, months (95% CI) 5.6 (2.8–8.4)
Overall survival  
Events, n (%) 40 (51.3)
Median, months (95% CI) 10.5 (8.7–12.3)
  1. CI confidence interval